Regeneron

$286.85
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$8.17 (-2.77%) Today
$0.00 (0.00%) As of 4:52 PM EDT after-hours

Why Robinhood?

You can buy or sell Regeneron and other stocks, options, ETFs, and crypto commission-free!

About REGN

Regeneron Pharmaceuticals, Inc. Common Stock, also called Regeneron, is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Read More It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Employees
7,400
Headquarters
Tarrytown, New York
Founded
1988
Market Cap
31.52B
Price-Earnings Ratio
15.94
Dividend Yield
0.00
Average Volume
621.11K
High Today
$296.26
Low Today
$285.57
Open Price
$293.96
Volume
815.21K
52 Week High
$442.00
52 Week Low
$285.55

Collections

REGN News

ReutersAug 14

Edited Transcript of REGN earnings conference call or presentation 6-Aug-19 12:30pm GMT

28
BenzingaAug 14

Regeneron's Drug To Treat Genetic Form Of Bad Cholesterol Aces Late-Stage Trial

56
BenzingaAug 14

The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering

18

REGN Earnings

$4.32
$5.16
$6.00
$6.84
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 5, Pre-Market

Popular Stocks

More REGN News

Barron'sAug 13

A Promising Ebola Drug Isn’t Helping Regeneron Stock. Here’s Why.

111
BenzingaAug 13

Regeneron's Eylea Prefilled Syringe Clears FDA Hurdle

15
MarketWatchAug 12

New experimental Ebola drugs are saving lives in Africa

38
ReutersAug 12

UPDATE 1-Congo Ebola treatment trial narrowed to two drugs showing promise

50
ReutersAug 12

Regeneron's Ebola treatment proves superior to rival in trial

9
ReutersAug 6

Regeneron beats second-quarter profit estimates on Eylea boost

75
MarketWatchAug 6

Regeneron stock up 2.2% after earnings beat

37
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.